|Bid||3.7100 x 800|
|Ask||3.7700 x 1000|
|Day's Range||3.5300 - 3.7700|
|52 Week Range||3.3500 - 7.8500|
|Beta (5Y Monthly)||2.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.17|
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -37.31% and 2.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2021 and highlighted corporate progress.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...